Quarterly Update – Test Volumes Fall Following Restructure

22 JANUARY 2023


CXBLADDER TEST VOLUMES FALL FOLLOWING RESTRUCTURE
DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today
announces tests processed at its laboratories weakened in the three months to the end of 31
December 2023, with the fall largely reflecting the reduction of the Commercial team in Q2 24.
The Sales team
1
, reduced amid continued uncertainty over whether Cxbladder will retain
Medicare coverage, now stands at 17 from its peak of 34, ahead of Novitas, the Medicare
Administrative Contractor with jurisdiction for Pacific Edge’s laboratories, releasing its non-
coverage determination in June 2023. Company-wide adaptation to the Q2 24 restructure and
the seasonal headwinds of holidays, reduced laboratory operating days and physician
schedules also contributed to the fall in US volumes.
In the three months to the end of December 2023 (Q3 24), the team processed 7,172 tests, a
15.9% reduction over the 8,525 tests processed in Q2 24 and a 7.7% reduction on the 7,768
tests processed in Q3 23.
The fall was led by US test volumes which were down 17.7% on Q2 24 at 6,040 and down
8.9% on Q3 23, while the number of clinicians ordering the test in Q3 24 fell to 1,016 from
1,147 in the prior quarter and 1,082 in Q3 23.
Tests per clinician were down on the prior quarter, but in line with seasonal expectations over
the quarter which included Christmas and Thanksgiving holidays. A new metric of sales force
efficiency, introduced today, measures the average sales by the average sales FTE
2
in each
quarter.
This has increased over the last two quarters despite the current headwinds. Test volumes in
the Asia Pacific in Q3 24 were 1,132, down 4.9% on the 1,190 tests processed in Q2 23 and
down 0.6% on the 1,139 tests processed in Q3 23. The move largely reflected seasonal
variations in the relatively mature New Zealand market.
Further details on test volumes and other developments in the quarter are included in the
investor update released today.
Released for an on behalf of Pacific Edge by Grant Gibson, Chief Financial Officer.
For more information:
Investors: Media:
Dr Peter Meintjes Richard Inder
Chief Executive The Project
Pacific Edge P: +64 21 645 643
P: 022 032 1263

1
The sales team includes Regional Sales Directors, National Accounts Executives, and Account Executives.
2
Average Sales FTE includes quarterly average total head count of Regional Sales Directors, National Account
Managers and Account Executives.

OVERVIEW
Pacific Edge: www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way
in the development and commercialization of bladder cancer diagnostic and prognostic tests
for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in
Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its
wholly owned, and CLIA certified, laboratories in New Zealand and the USA.
Cxbladder: www.cxbladder.com
Cxbladder is a urine-based genomic biomarker test optimized for the detection and surveillance
of bladder cancer. The Cxbladder evidence portfolio developed over the past 14 years includes
more than 20 peer reviewed publications for primary detection, surveillance, adjudication of
atypical urine cytology and equivocal cystoscopy. Cxbladder is the focal point of numerous
ongoing and planned clinical studies to generate an ever-increasing body of clinical utility
evidence supporting adoption and use in the clinic to improve patient health outcomes.
Cxbladder has been trusted by over 4,400 US urologists in the diagnosis and management of
more than 100,000 patients, including the option for in-home sample collection. In New
Zealand, Cxbladder is accessible to 75% of the population via public healthcare and all
residents have the option of buying the test online.

---

INSIDE
Letter from the CEO 2
Q3 24 test volumes 3
Kaiser test volumes build 5
Enhancing the clinician experience 5
New markets 6
Clinical studies update 7
JANUARY 2024

PACIFIC EDGE LIMITED INVESTOR UPDATE | JANUARY 2024
2
LETTER FROM THE CEO
PREPARED FOR ALL
OUTCOMES
1,2
Includes regional Regional Sales Directors, National Accounts Executives, and Account Executives.
Dear Shareholders,
Pacific Edge enters 2024 as we
ended 2023 – looking for certainty
on Medicare’s coverage of
Cxbladder.
I am frequently asked whether I
am optimistic or pessimistic about
retaining Medicare coverage for our
Cxbladder products, or alternatively
what a realistic outcome is. As
Chief Executive, I challenge the
framing that we must be optimistic,
pessimistic or realistic. The question
shareholders deserve an answer
to is: ‘does Pacific Edge have the
vision, the team, the work ethic and
the determination to get the job
done regardless of the headwinds
we face?’
To our shareholders, I say: ‘we
do – and we are prepared however
events unfold’.
It remains a fact that at any time
prior to 26 July 2024, Novitas, the
Medicare Administrative Contractor
with the jurisdiction for our US
laboratory, could re-publish as final
an unfavorable version of the draft
determination ‘Genetic testing for
oncology’ (DL39365) that would
see Medicare coverage cease for
Cxbladder products.
The ‘best case’ outcome,
however, is that Novitas recognizes
the merit of the evidence Pacific
Edge has submitted during the
‘Open Comment’ period that
ended on 9 September 2023, and
the series of highly supportive
representations from peers,
industry and the professional
urology community for Cxbladder
products to retain the ‘claim-by-
claim’ coverage, subject to medical
necessity, we have been afforded for
the last three and a half years.
“We are delivering
on a key goal from
the reorganization
in August for our
commercial team to
operate at breakeven”


We are meanwhile pleased to
have had the opportunity to meet in
November the Centers for Medicare
& Medicaid Services (CMS), the
body to whom Novitas is ultimately
accountable on coverage decisions.
This meeting precipitated a further
meeting with Novitas in January,
in which CMS representatives
also participated. We view the
involvement of CMS as a positive
engagement in response to the
seriousness of the issues we and
others have raised, but not definitive
of any particular outcome.
Even in the event that Cxbladder
products retain coverage, the
impact to our commercial
operations from the uncertainty we
have endured for 18 months have
already been substantial. The test
volume figures we have released
today demonstrate the cumulative
effects. US test volumes are now at
their lowest level since I assumed
leadership of Pacific Edge (see page
4) and, following the reorganization
undertaken in Q2 24, our sales force
is now at its smallest size.
The silver lining – and the correct
reading of this quarterly result – is
that the fall in test volume is due
principally to the reduction in the
size of our sales team
1
from 34 at
its peak in February 2023 to 17. It is
the inevitable consequence of the
steps necessary to preserve capital
given the elevated risks of a non-
coverage determination and an
acknowledgement that re-hiring for
departing account executives prior
to obtaining clarity from Novitas is
simply the wrong decision.
Despite this backdrop, our
commercial team has made
meaningful progress in other
important areas. Tests per ordering
clinician after allowing for seasonal
trends have held steady as we work
closely with our key customers.
Average tests per sales headcount
2
,
a new metric published for the first
time today, has actually increased
(see page 4). Furthermore, revenue
per test has increased (data not
released) predominantly as a result
of introducing our ‘Enhanced
Patient Responsibility’ and ‘Patient
Assist Programs’ which are aimed
at improving collections from
patients of private payers that deny

a Cxbladder claim. We are a better
business as a consequence of these
changes and will benefit when
we obtain coverage certainty – a
precursor for reverting to growth.
Without coverage certainty, we
do not have the ability to forecast a
return to growth in testing volume,
but we will continue to guide
investors to judge our performance
by the following key metrics –
throughput per sales headcount,
throughput per ordering clinician
and average sales price (ASP), all of
which are stable or increasing in the
current environment.
On the critical matter of
managing capital, we want
shareholders to understand that we
are delivering on a key goal from
the reorganization in August for
our commercial team to operate
at breakeven. The corollary of this
is that the cash outflow is driven
almost entirely by the strategic
imperatives of R&D for Detect
+

and Monitor
+
, technology transfer
from R&D to lab operations, clinical
evidence development for coverage
and guidelines inclusion, and the
digitalization and performance
excellence initiatives in the existing
operations.
Meanwhile, as we set out in this
shareholder update, we continue to
make Pacific Edge a more resilient
and efficient company. We are
building a presence in markets
in Asia and Latin America (and
Israel) that have lower barriers to
entry and allow us to leverage our
existing laboratory infrastructure
and support staff (see page 6). Our
performance excellence initiatives
are focused on improving customer
experience by reducing turnaround
time and the number of non-
resulted tests (see page 5). We
are making steady progress with
Kaiser Permanente, recording our
highest monthly test throughput in
December (see page 5), while our
clinical study program continues to
advance according to the timelines
we’ve previously set for investors
(see page 7).
We wish you a prosperous start
to the New Year and look forward to
reporting further progress to you in
April.
Dr Peter Meintjes
Chief Executive
TEST VOLUMES
TEAM REDUCTIONS WEIGH ON TEST VOLUMES
Cxbladder tests processed at Pacific Edge’s laboratories weakened in the three months to the end of
31 December 2023 with the fall largely reflecting the reduction of the commercial team in Q2 24.
The sales team
2
now stands at 17 from its peak of 34, ahead of the Medicare Administrative Contractor
Novitas releasing its non-coverage determination in June 2023. Company-wide adaption to the Q2 24 restructure
and the seasonal headwinds of holidays, reduced laboratory operating days and physician schedules also
contributed to the fall in US volumes.
In the three months to the end of December 2023 (Q3 24), the team processed 7,172 tests (Figure 1), a 15.9%
reduction over the 8,525 tests processed in Q2 24 and a 7.7% reduction on the 7,768 tests processed in Q3 23. The
fall was led by US test volumes which were down 17.7% on Q2 24 at 6,040 and down 8.9% on Q3 23, while the
number of clinicians ordering the test in Q3 24 fell to 1,016 from 1,147 in the prior quarter and 1,082 in Q3 23. Tests
per clinician were down on the prior quarter, but in line with seasonal expectations over the quarter which included
Christmas and Thanksgiving holidays (Figure 2).
The sales force efficiency metric described here measures the average sales by the average sales FTE
3
in each
quarter, and has increased over the last two quarters despite the current headwinds (Figure 3).
Test volumes in the Asia Pacific in Q3 24 were 1,132, down 4.9% on the 1,190 tests processed in Q2 23 and down
0.6% on the 1,139 tests processed in Q3 23. The move largely reflected seasonal variations in the relatively mature
New Zealand market.
2
The sales team includes Regional Sales Directors, National Accounts Executives, and Account Executives.
3
Average Sales FTE includes quarterly average total head count of Regional Sales Directors, National Account Managers and Account Executives.
PACIFIC EDGE LIMITED INVESTOR UPDATE | JANUARY 2024
3
LETTER FROM THE CEO CONTINUED

-
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
9,000
10,000
Test volume
US
Q3 21
3,110
4,053
Q4 21
3,824
1,073
4,897
Q1 22
4,277
1,079
5,356
Q2 22
4,706
1,074
5,780
Q3 22
4,591
1,117
5,708
Q4 22
5,290
952
6,242
Q1 23
6,073
983
7,056
Q2 23
6,699
1,165
7,864
Q3 23
6,629
1,139
7,768
Q4 23
7,817
1,061
8,877
Q1 24
8,627
1,077
9,704
Q2 24
7,335
1,190
8,525
Q3 24
6,040
1,132
7,172
943
APAC
-
200
400
600
800
1,000
1,200
1,400
1,600
-
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
US Ordering Clinicians
Tests/Clinician
US ORDERING CLINICIANS (LHS)
Q4 21
530
Q1 22
657
Q2 22
690
Q3 22
741
Q4 22
789
Q1 23
895
Q2 23
978
Q3 23
1,042
Q4 23
1,150
Q1 24
1,232
Q2 24
1,147
Q3 24
1,016
Q3 21
516
TESTS/ORDERING CLINICIANS (RHS)
6.0
7.2
7.0
6.5
6.8
6.2
6.1
6.7
6.8
6.8
6.4
5.9
6.8
-
10
20
30
40
50
60
-
50
100
150
300
200
250
Average Sales FTE
Average US Test Volume/Sales FTE
US AVERAGE SALES FTE (LHS)US TEST VOLUMES/SALES FTE (RHS)
200
202
160
187
222
226
201
239
288
265
292
21
Q1 22Q4 21Q3 21
23
Q2 22
29
Q3 22
28
Q4 22
27
Q1 23

30
Q2 23
33
Q3 23
33
Q4 23
30
Q1 24
28
Q2 24
21
Q3 24
-
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
9,000
10,000
Test volume
US
Q3 21
3,110
4,053
Q4 21
3,824
1,073
4,897
Q1 22
4,277
1,079
5,356
Q2 22
4,706
1,074
5,780
Q3 22
4,591
1,117
5,708
Q4 22
5,290
952
6,242
Q1 23
6,073
983
7,056
Q2 23
6,699
1,165
7,864
Q3 23
6,629
1,139
7,768
Q4 23
7,817
1,061
8,877
Q1 24
8,627
1,077
9,704
Q2 24
7,335
1,190
8,525
Q3 24
6,040
1,132
7,172
943
APAC
-
200
400
600
800
1,000
1,200
1,400
1,600
-
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
US Ordering Clinicians
Tests/Clinician
US ORDERING CLINICIANS (LHS)
Q4 21
530
Q1 22
657
Q2 22
690
Q3 22
741
Q4 22
789
Q1 23
895
Q2 23
978
Q3 23
1,042
Q4 23
1,150
Q1 24
1,232
Q2 24
1,147
Q3 24
1,016
Q3 21
516
TESTS/ORDERING CLINICIANS (RHS)
6.0
7.2
7.0
6.5
6.8
6.2
6.1
6.7
6.8
6.8
6.4
5.9
6.8
-
10
20
30
40
50
60
-
50
100
150
300
200
250
Average Sales FTE
Average US Test Volume/Sales FTE
US AVERAGE SALES FTE (LHS)US TEST VOLUMES/SALES FTE (RHS)
200
202
160
187
222
226
201
239
288
265
292
21
Q1 22Q4 21Q3 21
23
Q2 22
29
Q3 22
28
Q4 22
27
Q1 23

30
Q2 23
33
Q3 23
33
Q4 23
30
Q1 24
28
Q2 24
21
Q3 24
-
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
9,000
10,000
Test volume
US
Q3 21
3,110
4,053
Q4 21
3,824
1,073
4,897
Q1 22
4,277
1,079
5,356
Q2 22
4,706
1,074
5,780
Q3 22
4,591
1,117
5,708
Q4 22
5,290
952
6,242
Q1 23
6,073
983
7,056
Q2 23
6,699
1,165
7,864
Q3 23
6,629
1,139
7,768
Q4 23
7,817
1,061
8,877
Q1 24
8,627
1,077
9,704
Q2 24
7,335
1,190
8,525
Q3 24
6,040
1,132
7,172
943
APAC
-
200
400
600
800
1,000
1,200
1,400
1,600
-
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
US Ordering Clinicians
Tests/Clinician
US ORDERING CLINICIANS (LHS)
Q4 21
530
Q1 22
657
Q2 22
690
Q3 22
741
Q4 22
789
Q1 23
895
Q2 23
978
Q3 23
1,042
Q4 23
1,150
Q1 24
1,232
Q2 24
1,147
Q3 24
1,016
Q3 21
516
TESTS/ORDERING CLINICIANS (RHS)
6.0
7.2
7.0
6.5
6.8
6.2
6.1
6.7
6.8
6.8
6.4
5.9
6.8
-
10
20
30
40
50
60
-
50
100
150
300
200
250
Average Sales FTE
Average US Test Volume/Sales FTE
US AVERAGE SALES FTE (LHS)US TEST VOLUMES/SALES FTE (RHS)
200
202
160
187
222
226
201
239
288
265
292
21
Q1 22Q4 21Q3 21
23
Q2 22
29
Q3 22
28
Q4 22
27
Q1 23

30
Q2 23
33
Q3 23
33
Q4 23
30
Q1 24
28
Q2 24
21
Q3 24
FIGURE 1: TOTAL TEST VOLUMES
FIGURE 2: CXBLADDER CLINICAL ADOPTION
FIGURE 3: US SALES FORCE EFFICIENCY
TEST VOLUMES CONTINUED
PACIFIC EDGE LIMITED INVESTOR UPDATE | JANUARY 2024
4

KAISER PERMANENTE
TEST VOLUMES
BUILD AS EMR
GOES LIVE
Clinicians at Kaiser Permanente
within Southern California are
beginning to adopt Cxbladder
Triage and Monitor on agreed
patient types, having successfully
integrated Cxbladder ordering
with HealthConnect, the healthcare
provider’s electronic medical
records (EMR) system.
The integration of Cxbladder
tests into the EMR went live
mid-November and the initial
implementation went smoothly with
the Kaiser Permanente and Pacific
Edge teams quickly addressing
any operational issues that arose.
Clinicians across the urology medical
centers of the Southern California
Permanente Medical Group (Kaiser
Permanente SoCal) are adopting
the Cxbladder tests. The success
of the integration is now visible in
volumes ordered, with December
recording the highest volume from
the healthcare provider.
Kaiser Permanente is the largest
integrated healthcare provider in the
US, serving 12.6 million members,
which equates to approximately 3.7%
of the national population. Kaiser
Permanente’s Southern California
region is the largest region by
membership and manages the care
for approximately 37% of all patients
managed by the health plan. In
aggregate Kaiser Permanente SoCal’s
urology team conducts ~25,000
cystoscopies each year across the
relevant hematuria evaluation and
bladder cancer surveillance clinical
pathways. Kaiser Permanente and
Pacific Edge are collectively working
to further deliver the clinical value of
Cxbladder testing broadly to Kaiser
members in Southern California and
across the Kaiser system.
PACIFIC EDGE LIMITED INVESTOR UPDATE | JANUARY 2024
5
Faster Cxbladder turnaround times and the automation
of our laboratory processes - these are among the range
of performance excellence and Cxbladder simplification
initiatives we are pursuing to enhance the customer
experience and drive efficiencies in our operations.
The turnaround time project is focusing on processing
and documentation bottlenecks in the sample receipt,
accessioning and testing processes. The project is targeting
a reduction in the average amount of time between a sample
arriving at our laboratory door and the result being delivered
to clinicians.
In tandem with reducing turnaround time, we are
automating our RNA/DNA extraction process - the rate-
limiting step in our laboratory workflow. Automation not only
reduces the amount of time operators spend working with
samples, it also enhances the repeatability and reproducibility
of our tests. We are preparing for the technology transfer
of this development to our commercial labs where we will
document and publish for peer review the analytical validity
(AV) of the new automated workflow, further enhancing the
portfolio of evidence underpinning Cxbladder.
Chief Operating Officer Darrell Morgan says: “With reduced
test turnaround times clinicians are more quickly able to
use our tests to determine the appropriate management of
patients, while quicker results can help to alleviate patient
anxiety over their prognosis. Both outcomes enhance the
attractiveness of Cxbladder to all involved in the bladder
cancer patient care pathway.”
4
Repeatability measures the variation in measurements taken by a single instrument or person
under the same conditions, while reproducibility measures whether an entire study can be
reproduced in its entirety.
PERFORMANCE EXCELLENCE
ENHANCING THE CLINICIAN
EXPERIENCE

PACIFIC EDGE LIMITED INVESTOR UPDATE | JANUARY 2024
6
ASIA PACIFIC
NEW ASIAN MARKETS SEEING FIRST ORDERS
Commercial test volumes are slowly developing in
the new markets we’re approaching in Southeast
Asia, including the Philippines and Malaysia.
Volumes from these and the other markets
in which we are seeking partners, i.e. Indonesia,
Thailand, Hong Kong, and Vietnam, will not be
significant in the short and medium term. However,
over the longer term, as the clinical value of our tests
become recognised in each of these local urological
communities through the networks of our distributors,
the cumulative volume across these territories has
the potential to add meaningfully to the Pacific Edge
group.
In all of these regions our focus is on populations
that rely on the private healthcare systems. These
populations represent a minority of the more than
600 million
5
people in these countries. But, across
the regions we are considering, they represent a
serviceable market equal to the size of one large US
private payer or a medium-sized US state.
In such private systems the barriers to entry are
much lower than those found in markets that operate
universal healthcare schemes. Notably, healthcare
payers in our new markets are more likely to cover
tests if coverage is requested by clinicians who are
already using the tests, so payer coverage may follow
in certain markets after
initial clinician adoption.
We select partners
that have established
relationships with
clinical decision makers,
government and private
healthcare payers. In the
Philippines, for example,
we are partnered with
Hi-Precision Diagnostics,
a provider of pathology
lab services that operates
an extensive network of collection centres around
the country. In Malaysia, where healthcare payment
decisions are centralised around private hospitals and
their own pathology laboratories, we have teamed
up with a distributor, Wellspring Medical, which has a
team that is already calling on decision makers.
In all markets the relationships the distributor/
partner has with the clinicians is crucial. With the
support of Pacific Edge and its Medical Affairs team,
the partners in each market engage with clinicians the
same way the Medical Affairs Team reach out to US
clinicians - through conferences, symposia and face-
to-face meetings.
5
CIA Factbook 2023 estimates.

CLINICAL STUDIES
STRENGTHENING THE CLINICAL UTILITY CASE
STUDYGOALPOPULATION AND
USE
STATUS
STRATA
(Safe Testing of Risk
for AsymptomaTic
MicrohematuriA)
• CU for Triage
• CU for Detect
+

(retrospective)
• Microhematuria
• Risk stratification
- Enrolment is now closed with a total of
554 including 131 low risk patients Follow
up will continue until Q3 2024
- Data monitoring is underway and
expected to be completed Q1 2024
DRIVE
(Detection and Risk
stratification In VEterans
presenting with
hematuria)
• CV for Detect
+

• CV for Triage and
within a Veterans’
cohort
• Data for pooled
analysis
• Micro and gross
hematuria
• Risk stratification
- Enrolment total is 672 across 11 US sites
and in line with target
- Enrolment is expected to close early 2024
with follow up continuing until Q3 2024
microDRIVE
(Detection and Risk
stratification In VEterans
presenting with
hematuria)
• CV of Detect
+

• Data for pooled
analysis
• Microhematuria
• Detection
- Recruitment commenced November 2023
as a network study across all VAMCs
coordinated from a single US VA site
- A total of 23 patients have consented for
the study with 5 samples received to date
- The target is 1000 patients with 35-50
tumor confirmed patients
- Last patient in: May/June 2024
AUSSIE
(Australian Urologic risk
Stratification of patientS
wIth hEmaturia)
• CV of Detect
+

with an Australian
cohort
• Data for pooled
analysis
• Micro and gross
hematuria
• Risk stratification
- Target enrolment: 600 patients across
three Australian sites
- Enrolment commenced August 2023 and
42 subjects are enrolled to date
POOLED ANALYSIS• CV of Detect
+
• Microhematuria
• Risk stratification
- Microhematuria patients from DRIVE,
AUSSIE and microDRIVE will be pooled
and performance determined
- The projected analysis is Q3 2025
LOBSTER
(LOngitudinal Bladder
cancer Study for
Tumor Recurrence)
• CV of Monitor/
Monitor
+
• Surveillance
• Risk stratification
- Target enrollment is 426 subjects across
10 sites (US, Australia)
- Enrolment is now 205 subjects with 285
samples received to date
- The enrolment phase is expected to end
late 2024
CREDIBLE
(Cystoscopic REDuction
In BLadder Evaluations
for microhematuria) - A
randomized, controlled,
clinical utility study for
hematuria evaluation
• CU of Detect
+
• Microhematuria
• Risk stratification
- Target enrollment is 1000 subjects with an
interim analysis at 600 to determine if the
primary objective has been addressed
- Due to commence late 2024
*Dates are calendar year not financial years
Clinical Utility (CU) - Evidence a test that can usefully change patient management within the context of care for
the defined population and indication.
Clinical Validity (CV) - Evidence a test works in the same way on an independent eligible population for a given
indication.
Analytical validity (AV) - Evidence a test is repeatable in the lab for a given indication and population.
Visit the Pacific Edge website to learn more about the strategic rationale for our studies.
PACIFIC EDGE LIMITED INVESTOR UPDATE | JANUARY 2024
7

ABOUT US
Pacific Edge Limited (NZX/ASX: PEB) is a global cancer diagnostics company leading the way in the development
and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria
or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of
Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.
VISIT US ONLINE:
www.pacificedgedx.com
www.cxbladder.com
FOLLOW US ON SOCIAL MEDIA:
www.facebook.com/PacificEdgeLtd
www.facebook.com/Cxbladder
www.twitter.com/PacificEdgeLtd
www.twitter.com/Cxbladder
www.linkedin.com/company/pacific-edge-ltd
CONTACT US:
Centre for Innovation
87 St David Street
PO Box 56
Dunedin 9016, New Zealandd
T: 0800 555 563 (NZ)
+64 3 577 6733 (Overseas)
E: investors@pacificedge.co.nz